•
Sep 26, 2020

Waters Q3 2020 Earnings Report

Waters' Q3 2020 financial performance reflected growth driven by pharmaceutical and industrial end markets and expansion in the U.S., Europe, and China.

Key Takeaways

Waters Corporation reported Q3 2020 sales of $594 million, a 3% increase compared to Q3 2019. GAAP EPS decreased to $2.03, while non-GAAP EPS increased to $2.16. Adjusted free cash flow was strong at $190 million, a 53% increase from the prior year.

Sales of $594 million grew 3% as reported and 2% in constant currency.

Year-over-year sales increase driven by pharmaceutical and industrial end markets.

Growth in the U.S., Europe, and China, partially offset by declines in other areas.

Strong adjusted free cash flow of $190 million, a 53% increase from prior year.

Total Revenue
$594M
Previous year: $577M
+2.9%
EPS
$2.16
Previous year: $2.13
+1.4%
Pharma Market Sales
5%
0
Industrial Market Sales
5%
0
Academic & Gov Sales
-8%
0
Gross Profit
$331M
Previous year: $336M
-1.4%
Cash and Equivalents
$375M
Previous year: $405M
-7.3%
Free Cash Flow
$190M
Total Assets
$2.68B
Previous year: $2.56B
+4.6%

Waters

Waters

Waters Revenue by Geographic Location

Forward Guidance

Waters Corporation acknowledges the ongoing variability expected in end markets during the fourth quarter and is focusing on improving commercial execution and product development efforts.

Revenue & Expenses

Visualization of income flow from segment revenue to net income